Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)
India · Delayed Price · Currency is INR 103.00
0.00 (0.00%)
At close: Sep 2, 2026
NSE:ARISTO Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 701 | 511 | 791 | 425 | 382 | - | |
Market Cap Growth | -14.59% | -35.46% | 86.07% | 11.42% | - | - |
Enterprise Value | 1,029 | 837 | 986 | 661 | 662 | - |
Last Close Price | 103.00 | 75.00 | 115.72 | 61.96 | 55.44 | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 9.76 | 7.11 | 19.47 | 10.91 | 10.71 | - |
PS Ratio | 0.19 | 0.14 | 0.25 | 0.17 | 0.18 | - |
PB Ratio | 1.58 | 1.15 | 2.12 | 1.26 | 1.26 | - |
P/TBV Ratio | 1.58 | 1.15 | 2.12 | 1.26 | 1.26 | - |
P/FCF Ratio | 12.79 | 9.31 | 16.11 | 40.66 | - | - |
P/OCF Ratio | 8.30 | 6.05 | 7.90 | 5.59 | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 0.28 | 0.23 | 0.31 | 0.27 | 0.30 | - |
EV/EBITDA Ratio | 6.41 | 5.21 | 10.40 | 7.72 | 7.53 | - |
EV/EBIT Ratio | 7.84 | 6.37 | 14.33 | 9.46 | 9.12 | - |
EV/FCF Ratio | 18.77 | 15.26 | 20.09 | 63.25 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.80 | 0.80 | 0.59 | 0.62 | 0.75 | 1.71 |
Debt / EBITDA Ratio | 2.21 | 2.21 | 2.30 | 2.44 | 2.56 | 4.87 |
Debt / FCF Ratio | 6.46 | 6.46 | 4.45 | 19.97 | - | 7.22 |
Net Debt / Equity Ratio | 0.74 | 0.74 | 0.47 | 0.46 | 0.62 | 1.54 |
Net Debt / EBITDA Ratio | 2.04 | 2.04 | 1.85 | 1.81 | 2.13 | 4.37 |
Net Debt / FCF Ratio | 5.98 | 5.98 | 3.58 | 14.79 | -2.73 | 6.48 |
Asset Turnover | 2.46 | 2.46 | 2.38 | 2.16 | 2.46 | 2.09 |
Inventory Turnover | 5.98 | 5.98 | 6.76 | 6.38 | 7.11 | 5.23 |
Quick Ratio | 0.56 | 0.56 | 0.63 | 0.75 | 0.85 | 0.70 |
Current Ratio | 1.26 | 1.26 | 1.21 | 1.26 | 1.39 | 1.23 |
Return on Equity (ROE) | 17.55% | 17.55% | 11.46% | 12.22% | 15.82% | 10.15% |
Return on Assets (ROA) | 5.55% | 5.55% | 3.21% | 3.85% | 5.13% | 3.26% |
Return on Invested Capital (ROIC) | 12.58% | 14.71% | 9.84% | 10.29% | 12.60% | 8.17% |
Return on Capital Employed (ROCE) | 25.20% | 25.20% | 15.30% | 16.00% | 18.00% | 15.90% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 10.24% | 14.07% | 5.14% | 9.16% | 9.34% | - |
FCF Yield | 7.82% | 10.74% | 6.21% | 2.46% | -17.94% | - |
Dividend Yield | 0.58% | 0.80% | 0.43% | 0.65% | 0.45% | - |
Payout Ratio | - | - | 8.38% | 11.36% | - | - |
Buyback Yield / Dilution | -0.01% | -0.01% | - | -28.43% | -6.13% | - |
Total Shareholder Return | 0.58% | 0.80% | 0.43% | -27.78% | -5.67% | - |